Medindia

X

Humira Replaces Enbrel as the Therapy Perceived by Dermatologists to be the Most Efficacious for the Treatment of Moderate to Severe Psoriasis

Tuesday, March 23, 2010 General News J E 4
Advertisement
Stelara Will Retain Decision Resources' Clinical Gold-Standard Status Through 2018 for Moderate to Severe Psoriasis, According to a New Report from Decision Resources

For more information, contact:

Decision Resources

Decision Resources, Inc.

Lisa Osgood

Christopher Comfort

781-296-2606

781-296-2597

losgood@hl-isy.com

ccomfort@dresources.com  

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Uninsured in Atlanta Area to Receive Help as Healt...
S
Bevacizumab/Paclitaxel/Carboplatin Will Remain Dec...